Tp-cso: a triptolide prodrug for pancreatic cancer treatment

HIGHLIGHTS

  • who: Xinlong Wang et al. from the Academy of Chinese Medicine Sciences, Henan University of Chinese Medicine, Zhengzhou, China have published the research work: TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment, in the Journal: Molecules 2022, 27, 3686. of /2022/
  • what: A TP-CSO prodrug was synthesized and characterized by 1 H NMR, FTIR spectrum, DSC and XRD analysis.
  • how: The result indicated that the TP moiety was successfully introduced into the CSO backbone. The above results showed that the TP-CSO conjugate had been successfully synthesized through the coupling of . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?